Jason Gale报道：CSL有限公司同意支付高达16亿美元，共同开发和销售一种针对罕见肾脏和肝脏疾病的实验性治疗药物，进一步拓展这家澳大利亚生物技术公司在肾脏医药领域的布局。
Ltd. agreed to pay as much as $1.6 billion to jointly develop and sell an experimental treatment for rare kidney and liver diseases, expanding the Australian biotech company’s push into kidney medicine.
CSL周一在声明中表示，将向瑞士药物开发商Alentis Therapeutics AG支付3.55亿美元的首付款，如果该疗法lixudebart（利苏德巴特）达到特定商业里程碑，Alentis还有资格获得高达12亿美元的额外款项。
CSL will pay Alentis Therapeutics AG $355 million upfront, with the Swiss drug developer eligible for as much as $1.2 billion more if the treatment, lixudebart, reaches certain commercial milestones, CSL said in a statement Monday.
该疗法正在针对一种可迅速并永久损害肾脏的罕见自身免疫性疾病患者进行中阶段临床试验。
The treatment is being tested in a mid-stage trial in people with a rare autoimmune disease that can rapidly and permanently damage the kidneys.
这笔交易为CSL在其成熟的血浆制品和疫苗业务之外确定的扩张领域增添了另一种潜在疗法。
The deal gives CSL another potential therapy in an area it has identified for expansion beyond its established blood-plasma and vaccine businesses.
Lixudebart旨在同时解决可能导致永久性器官损伤的炎症和纤维化问题，两家公司还计划针对另一种慢性肾脏疾病和一种肝脏疾病进行测试，CSL表示目前尚无针对该肝病的可用治疗方法。
Lixudebart is designed to tackle both inflammation and scarring that can lead to lasting organ damage, and the companies also plan to test it against another chronic kidney disorder and a liver disease for which CSL says there is currently no available treatment.
CSL将资助完成目前的中阶段肾脏试验、计划中的晚期研究以及针对另外两种疾病的试验。
CSL will fund completion of the current mid-stage kidney trial, a planned late-stage study and trials in the two other diseases.
如果该药物上市，CSL将获得全球利润的55%，Alentis获得45%。
If the drug reaches the market, CSL will receive 55% of global profits and Alentis 45%.
CSL表示，正在进行的试验中26名患者的中期分析显示，24周后肾功能指标有所改善。该药物仍处于实验阶段，尚未获批用于这些适应症。
An interim analysis of 26 patients in the ongoing trial showed improvement in measures of kidney function after 24 weeks, CSL said. The drug is still experimental and hasn’t been approved for these uses.